Twelve active acromegalic @entity1 (10 @entity1 , 2 @entity1 ) were chronically treated with a long-acting microcapsulated preparation of @entity2390 (Sandostatin LAR, Novartis). In each case, a @entity2124 -producing pituitary @entity652 was responsible for the development of @entity2012 (microadenomas in 3 and macroadenomas in the rest of the @entity1 ). Treatment with long-acting @entity2390 was indicated for those @entity1 who had not reacted satisfactorily upon previous therapeutic procedures or proved to be unsuitable for irradiation therapy and/or surgery or refused both of these therapies. The preparation was given intramuscularly in every fourth week, generally in a dose of 20-30 mg. After a 6-month treatment, the daily mean of serum @entity2124 became suppressed below 2.5 ng/ml in 58.3% of the @entity1 , whereas the @entity2124 nadir during oral @entity413 tolerance test was found at or below 2.5 ng/ml in an even higher proportion of @entity1 (70%). During a 2-year period, the @entity2124 -suppressive effect of long-acting @entity2390 remained stable in all but one @entity1 . The size of the @entity977 remarkably decreased in 50% of this @entity1 cohort. The medication with this preparation was well tolerated. As adverse events, asymptomatic @entity2963 was detected in 2 @entity1 and biliary sludge-formation in 1 @entity1 . The total number of @entity1 with @entity413 metabolism disturbances increased only moderately, however, the occurrence of manifest @entity6 became doubled. On the basis of relevant literature data, it can be stated that the mortality rate of successfully treated acromegalics significantly improves. The present retrospective study yields evidence for the microcapsulated @entity2390 to be an effective tool in the modern therapy of @entity2012 .

[Current alternative in the pharmacotherapy of @entity2012 : the long-acting somatostatin analogue XXXX ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity2124 :: ('2688', 'Gene') :: ['growth hormone'] @entity2012 :: ('MESH:D000172', 'Disease') :: ['acromegaly'] @entity2963 :: ('MESH:D002769', 'Disease') :: ['cholelithiasis'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenomas'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenoma'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2390 :: (MESH:D015282,Chemical) :: ['octreotide']
